Trajectum Pharma Overview

  • Founded
  • 2010
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private

Trajectum Pharma General Information


Developer of a tolerance-inducing cell therapy designed to treat autoimmune inflammatory diseases. The company's therapy is built on a deep-rooted understanding of immunologic functions in health and disease to develop an off-the-shelf vaccine for RA or possibly use CAR-T cells to induce tolerance, enabling physicians to treat autoimmune inflammatory diseases in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • PO Box 85459
  • 3508 AL Utrecht
  • Netherlands
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Trajectum Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 00000 Completed Generating Revenue
3. Seed Round 01-Jan-2020 00000 Completed Generating Revenue
2. Seed Round 01-Jul-2010 $136K $136K Completed Generating Revenue
1. Grant 01-Jun-2010 $31.3K Completed Generating Revenue
To view Trajectum Pharma’s complete valuation and funding history, request access »

Trajectum Pharma Executive Team (2)

Name Title Board Seat Contact Info
Willem van Eden Ph.D Co-Founder, Scientific Director & Chief Scientific Officer
Paul Leufkens Co-Founder & Chief Executive Officer
To view Trajectum Pharma’s complete executive team members history, request access »